Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.
Checked against the public recordLast updated Nov 27, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Fox Chase Cancer Center
- Interventions being studied
- Drug: vorinostat
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * biopsy proven non-squamous NSCLC with unresectable stage IIIA or dry IIIB disease. * FEV1 \>/= 1 liter * ECOG PS 0 or 1 * Able to swallow and absorb enterally * Measurable disease per RECIST 1.1 * Adequate organ and marrow function including calculated creatinine clearance \>/= 60 mL/min hepatic enzymes and alk phos \</= 2.5 X ULN. Exclusion Criteria: * Chemotherapy or radiotherapy \</= 4 weeks prior to registration (6 weeks for nitrosureas) * Active bleeding * Known brain mets * Prior thoracic radiotherapy that would lead to overlap with current radiation field. * More than 10% weight loss in 6 months. * Pancoast tumors, supraclavicular or contralateral hilar lymph node involvement * Known HIV positive * Prior treatment with an HDAC inhibitor
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Moffitt Cancer CenterTampa, Florida
- Fox Chase Cancer CenterPhiladelphia, Pennsylvania
- Medical University of South CarolinaCharleston, South Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 27, 2019. Always confirm current availability with the study team.